Efficacy and Safety of [<sup>225</sup>Ac]Ac-PSMA-617 Augmented [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis

Efficacy and Safety of [<sup>225</sup>Ac]Ac-PSMA-617 Augmented [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis

The use of <sup>225</sup>Ac in prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), either as monotherapy or in combination with <sup>177</sup>Lu, is a promising therapy approach in patients with metastatic castration-resistant prostate carcinoma (mCR...

Full description

Bibliographic Details
Main Authors: Florian Rosar, Jonas Krause, Mark Bartholomä, Stephan Maus, Tobias Stemler, Ina Hierlmeier, Johannes Linxweiler, Samer Ezziddin, Fadi Khreish
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Pharmaceutics
Subjects:
metastatic castration-resistant prostate cancer
<sup>225</sup>Ac and <sup>177</sup>Lu
PSMA radioligand therapy
biochemical response
molecular imaging response
efficacy
Online Access:https://www.mdpi.com/1999-4923/13/5/722

Internet

https://www.mdpi.com/1999-4923/13/5/722

Similar Items